Last reviewed · How we verify
GRANISETRON HYDROCHLORIDE
At a glance
| Generic name | GRANISETRON HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
Common side effects
- Headache
- Constipation
- Asthenia
- Diarrhea
- Abdominal pain
- Dyspepsia
- Nausea
- Vomiting
- Elevation of AST
- Elevation of ALT
- Hypertension
- Dizziness
Key clinical trials
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Occlusal Splint Combined With Granisetron Injection for Management of Myofascial Pain Related to Temporomandibular Disorders (PHASE4)
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- Staccato® Granisetron Single Dose PK (PHASE1)
- Granisetron 1 mg Tablets, Non-fasting (PHASE1)
- Granisetron 1 mg Tablets Under Fasting Conditions (PHASE1)
- PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron (PHASE1)
- Intravenous Lidocaine on Chronic Pain in Patients Undergoing Hepatectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRANISETRON HYDROCHLORIDE CI brief — competitive landscape report
- GRANISETRON HYDROCHLORIDE updates RSS · CI watch RSS